US FDA approves Mounjaro to reduce cardiovascular risk

The FDA has officially approved its diabetes drug Lilly’s Mounjaro to prevent a heart attack or stroke in adults with type 2 diabetes who are at high risk of cardiovascular events on Friday.

Mounjaro is the primary drug that targets the GLP-1 protein and is also used for weight loss. Meanwhile, recent approval was based on remarkable results from a trial showing Mounjaro outperformed Trulicity.

Lilly’s older diabetes drug in lowering cardiovascular events in a robust comparative trial. The trial established that Mounjaro prevented severe heart complications by 8% more than Trulicity. It has been observed that the sales of Mounjaro rose 91% to $9.94 billion in the second quarter as robust demand boosted global revenue.

Danish rival Novo Nordisk secured FDA approval for its weight-loss drug, Wegovy, for lowering heart risks in metabolically obese adults with heart disease in 2024, as reported by the Reuters.

Lilly and Novo are both striving to expand their impact on GLP-1 drugs, while testing them in conditions ranging from cardiovascular disease to liver disorders.

Additionally, the FDA already approved its older diabetes drug, Rybelsus in 2025 to lower the risk of major heart diseases in diabetic patients.